Drug-induced Hyperthermic Syndromes in Psychiatry

Stanley N. Caroff, Charles B. Watson, Henry Rosenberg

1Corporal Michael J. Crescenz VA Medical Center, 2Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA, 3Malignant Hyperthermia Association of the United States, Sherburne, NY, USA

Hyperthermia, or extreme elevations in body temperature, can be life-threatening and may be caused by prescription drugs or illegal substances acting at a number of different levels of the neuraxis. Several psychotropic drug classes and combinations have been associated with a classic clinical syndrome of hyperthermia, skeletal muscle hypermetabolism, rigidity or rhabdomyolysis, autonomic dysfunction and altered mental status ranging from catatonic stupor to coma. It is critical for clinicians to have a high index of suspicion for these relatively uncommon drug-induced adverse effects and to become familiar with their management to prevent serious morbidity and mortality. Although these syndromes look alike, they are triggered by quite different mechanisms, and apart from the need to withdraw or restore potential triggering drugs and provide intensive medical care, specific treatments may vary. Clinical similarities have led to theoretical speculations about common mechanisms and shared genetic predispositions underlying these syndromes, suggesting that there may be a common “thermic stress syndrome” triggered in humans and animal models by a variety of pharmacological or environmental challenges.

KEY WORDS: Induced hyperthermia; Malignant hyperthermia; Neuroleptic malignant syndrome; Serotonin syndrome; Antipsychotic agents; Substance use disorders.

INTRODUCTION

Maintenance of normal body temperature, or thermoregulation, is essential to health [1]. Body temperature is one of the most tightly regulated vital functions. Thermoregulation is a complex physiologic process involving multiple levels of the nervous system as well as other body organs and systems. As a result, there are many steps that can be affected by drugs or toxins which impair thermoregulation and lead to hyperthermia.

While it is important for clinicians to be familiar with all drugs that interfere with thermoregulation, one category consists of drugs that cause hyperthermia at least in part by increasing internal heat production in the absence of a hot environment (Table 1, Fig. 1) [2]. These syndromes, characterized by contraction and hypermetabolism of skeletal muscle, manifest elevated temperatures, muscle rigidity, rhabdomyolysis, elevated vital signs, and changes in mental status that closely resemble malignant hyperthermia of anesthesia (MHA) [3-6]. This clinical picture can be a medical emergency with risk of serious complications and death (Table 2).

While these syndromes frequently present in emergency units, they also may be encountered and should be considered during consultations in psychiatric and medical hospital settings. For example, polypharmacy is common, especially among the elderly, such that patients receiving neuropsychiatric treatment who develop hyperthermia often have been taking multiple potential triggering drugs. The association of several drugs (e.g., certain antiemetics, antibiotics, herbal remedies) with risk of hyperthermic reactions is not well recognized. Finally, since the management of these syndromes may vary in preventing serious adverse outcomes, the differential diagnosis is important.

This overview describes a selection of drug-induced hyperthermic syndromes that consulting psychiatrists
| Clinical Features | Malignant Hyperthermia | Neuroleptic Malignant Syndrome | Serotonin Syndrome | Parkinsonism Hyperpyrexia Syndrome | Baclofen Withdrawal Syndrome | Adrenergic Stimulation/ Psychedelics | Oxidative Phosphorylation Uncouplers | Anticholinergic Syndrome |
|-------------------|------------------------|-------------------------------|-------------------|-----------------------------------|---------------------------|----------------------------------|-------------------------------|-------------------------|
| **Drug triggers** | Inhalational anesthetics, succinylcholine | Dopamine antagonists | Serotonergic agents; SSRI, SNRI or MAOI antidepressants, some opioids, triptans, antibiotics (linezolid), tryptophan, St. John’s wort, MDMA, methylene blue | Withdrawal or failure of dopaminergic drugs, loss of DBS stimulation | Withdrawal of baclofen, failure of intrathecal pump | Amphetamine, MDMA, cocaine, cathinones, ketamine, phencyclidine, LSD, psilocybin, mescaline | Salicylates, 2,4-dinitrophenol | Antiparkinsonian, antipsychotic, antidepressant, antihistaminic, or ocular drug, over-the-counter and herbal products |
| **Clinical signs** | Hyperthermia, rigidity, autonomic dysfunction, tachypnea, rhabdomyolysis | Hyperthermia rigidity, tremor, autonomic dysfunction, rhabdomyolysis, sweating, altered mental status | Mild: Agitation, tremor, autonomic dysfunction, altered mental status | Hyperthermia, rigidity, tremor, autonomic dysfunction, altered mental status | Hyperthermia, rigidity, tremor, autonomic dysfunction, altered mental status, seizures | Mild: Agitation, tachycardia, confusion, dilated and reactive pupils, ataxia, hypertension, rigidity or agitation, sweating, catatonia | Severe: Hypertensive retinopathy, arrhythmia, oliguria, rhabdomyolysis, altered mental status |
| **Laboratory studies** | Hypercarbia, acidosis, hyperkalemia, elevated CK, leukocytosis, EEG slowing | Acidosisis, hypoxia, elevated CK, leukocytosis, EKG slowing | Acidosisis, elevated CK | Elevated CK, leukocytosis | Elevated CK | Blood salicylate levels | Elevated CK | Tricyclic antidepressant levels, EKG findings |
| **Frequency** | 1:10,000 to 1:250,000 anesthetics | 0.02 – 0.11% patients receiving antipsychotics | 0.09 – 0.23% patients receiving SSRI antidepressants | 0.3 – 3.6% PD patients receiving and withdrawn from levodopa | | | | |
Table 1. Continued

| Clinical Features | Malignant Hyperthermia | Neuroleptic Malignant Syndrome | Serotonin Syndrome | Parkinsonism Hyperpyrexia Syndrome | Baclofen Withdrawal Syndrome | Adrenergic Stimulation/Phosphorylation Uncouplers | Oxidative Phosphorylation Uncouplers | Anticholinergic Syndrome |
|-------------------|------------------------|-------------------------------|-------------------|-----------------------------------|-----------------------------|-----------------------------------------------|--------------------------------|-------------------------|
| Mortality Risk factors | 1–5% | 5–20% (MDMA: “rave” dance parties) | 5% | 15% | Intrathecal infusion pump, high level spinal cord injury, cerebral spasticity or dystonia | Substance use disorders, ambient temperature (MDMA: “rave” dance parties) | Overdose, weight loss regimens | Older adults, overdose, drug combinations |
| Treatment | Cessation of anesthesia, intensive care, intravenous dantrolene | Cessation of dopamine antagonists, intensive care | Cessation of serotonergic drugs, intensive care | Re-store dopaminergic drugs, intensive care, cyproheptadine, benzodiazepines, dantrolene | Re-store baclofen, intensive care, re-establish pump function, benzodiazepines | Cessation of adrenergic stimulants and psychedelics, intensive care | Cessation of oxidative phosphorylation uncoupling drugs, intensive care, salicylates; gastric lavage, alkalinate blood and urine, hemodialysis | Cessation of anticholinergic drugs, physostigmine for severe cases (risk of cholinergic crisis, seizures, heart block in tricyclic antidepressant overdose) |

SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor; MAOI, monoamine oxidase inhibitor; MDMA, 3,4-methylenedioxymethamphetamine; DBS, deep brain stimulation; LSD, lysergic acid diethylamide; GI, gastrointestinal; CK, creatine kinase; EEG, electroencephalogram; EKG, electrocardiogram; ECT, electroconvulsive therapy; PD, Parkinson’s disease; RYR1, ryanodine receptor-1.
may encounter in daily practice. While these syndromes primarily reflect extreme hyperthermia due to drug-induced increases in internal heat production, the anticholinergic syndrome which results in hyperthermia mostly by inhibiting peripheral heat loss is also covered for completeness. Other medical disorders in the extensive differential diagnosis of extreme hyperthermia (e.g., exertional heatstroke, encephalitis, sepsis, etc.) that are not drug-induced are equally important but beyond the scope of this review. In addition, there are a number of theoretical speculations about common mechanisms and shared genetic predispositions underlying these syndromes, which suggest that there may be a common “thermic stress syndrome” that can be triggered in humans and animal models by a variety of pharmacological or environmental challenges (Fig. 1) [7-9]. Although this concept is intriguing in predicting risk and understanding the pathophysiology of these disorders, it is also beyond the objective of this review which focuses instead on the practical clinical recognition and management of these drug-induced syndromes.

HYPERTHERMIC SYNDROMES

Malignant Hyperthermia of Anesthesia

MH is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent inhalational volatile agents and the depolarizing muscle relaxant succinylcholine [10,11]. While it is encountered primarily during anesthesia, MH-susceptibility is increasingly recognized as predisposing to hyperthermic episodes due to heat or other stresses outside the operating theater. As such, the MH syndrome serves as the prototype of acute drug-induced hyperthermia and has received the most advanced research on the underlying pathophysiology and genetic mechanisms. Practically, in
post-operative and critical care settings, psychiatrists may be consulted to differentiate MH from other drug-induced syndromes discussed below and therefore should be familiar with its clinical features.

Standardized diagnostic criteria of MH include hyperthermia, tachycardia, tachypnea, increased carbon dioxide production, increased oxygen consumption, mixed metabolic and respiratory acidosis, hyperkalemia, muscle rigidity, and rhabdomyolysis [12]. The estimated incidence of MH reactions ranges from 1:10,000 to 1:250,000 anesthetics. The diagnosis can be confirmed by an in vitro skeletal muscle contracture test. In humans, MH-susceptibility is inherited in an autosomal dominant pattern and has been mapped in up to 50−70% or more of cases to variants in the ryanodine receptor-1 gene (RYR1) on chromosome 19q13.1 affecting calcium sequestration in the sarcoplasmic reticulum.

Treatment of MH episodes with intravenous dantrolene to inhibit calcium release into muscle cytoplasm has resulted in reduction of the expected mortality due to MH from >70−80% to as low as 1.4−5% in North America [11].

Neuroleptic Malignant Syndrome

Estimates of the incidence of Neuroleptic Malignant Syndrome (NMS) range from 0.02−0.11% of patients treated with dopamine blocking agents, primarily antipsychotics [13-15]. Haloperidol, used frequently for sedation in critical care, is associated with NMS in nearly half of reported cases. Although the incidence and mortality of NMS may have diminished with the introduction of newer less potent antipsychotics, it remains potentially lethal if neglected. NMS also results from treatment with dopamine blocking drugs used to prevent nausea (metoclopramide, prochlorperazine) [16], and rarely dopamine depleting drugs (tetrabenazine, valbenazine, deutetraphenazine) [17].

Risk factors for NMS include dehydration, exhaustion, agitation, catatonia, previous NMS episodes, and rapidly increasing doses of high potency antipsychotics [18]. Recent case reports suggest that patients with underlying encephalitis may be at risk for NMS when treated with antipsychotics [19,20]. NMS may develop within hours, but usually evolves over a few days. Most cases occur within 1−2 weeks after drugs are started. Standardized diagnostic criteria have been validated and include elevated temperatures, rigidity, tremors, altered consciousness, and changes in vital signs [21,22]. Laboratory abnormalities, including muscle enzyme elevations (creatine kinase), acidosis and hypoxia, are common. No single test confirms the diagnosis, but thorough evaluation is essential to exclude other medical conditions. While elevated serum creatine kinase elevations are observed with antipsychotics and in cases of NMS, they are non-specific and not pathognomonic [23,24]. While antipsychotics and other psychotropics may also contribute to heatstroke in hot environments by inhibiting central and peripheral heat loss mechanisms [25], NMS can be distinguished from heatstroke by the presence of rigidity and stupor as opposed to flaccidity and delirium. In addition, hyperthermia in NMS is derived from an internally generated heat load and occurs independent of ambient temperatures.

Evidence strongly implicates drug-induced blockade of brain dopamine receptors as the primary triggering mechanism as opposed to MH which is triggered primarily in skeletal muscle (Fig. 1). Other evidence indicates that NMS and MH are different disorders; muscle contracture tests in patients with NMS have been negative for MH-susceptibility; case reports of RYR1 pathogenic variants in NMS patients are inconclusive; NMS patients and family members have had anesthesia without adverse effects; NMS but not MH symptoms are reversed by peripheral-acting skeletal muscle relaxants; NMS has never been reported to occur intraoperatively [26].

Once antipsychotics are withdrawn, most NMS cases resolve within 1−2 weeks, although patients may have prolonged symptoms if long-acting antipsychotics were received. A few patients develop a prolonged residual state that may respond to electroconvulsive therapy (ECT). The primary treatment of NMS consists of early diagnosis, discontinuing neuroleptics and supportive medical care. In the absence of randomized controlled trials, benzodiazepines, dopamine agonists, dantrolene and ECT have been used empirically with varying success.

For additional information, the Neuroleptic Malignant Syndrome Information Service, a subsidiary of the Malignant Hyperthermia Association of the United States, offers additional resources (www.nmsis.org).

Parkinsonism-Hyperpyrexia Syndrome

Patients with Parkinson’s disease (PD) and related disorders (e.g., Lewy body dementia,) are at risk for severe
fluctuations of motor symptoms. Although rigidity, tremors and bradykinesia are effectively controlled by dopaminergic drugs, patients are sensitive to dosing changes. In particular, patients may develop a Parkinsonism-Hyperpyrexia Syndrome (PHS) indistinguishable from NMS and MH following abrupt decreases in dopaminergic medication [27]. Dopamine depletion correlates with risk of developing PHS based on findings of lower homovanillic acid levels in spinal fluid and reduced striatal dopamine transporter binding on single-photon emission computerized tomography imaging in susceptible patients [27-29].

PHS is reported in the context of non-compliance with dopaminergic medications, during severe "off" periods, concurrent illness, dysphagia or changes in diet, and withholding of medications prior to medical or surgical procedures [30,31]. For example, PHS may be observed after surgery in patients with PD instructed to stop dopaminergic medications prior to surgery and not restarted promptly post-operatively. PHS may also emerge in PD patients after implantation of electrodes for deep brain stimulation (DBS), due to reduction of dopaminergic drugs or sudden loss of DBS stimulation (battery failure, explantation) [32,33]. Reports suggest PHS may occur in 0.3−3.6% of PD patients treated with and withdrawn from levodopa, and several deaths have been reported. Symptoms develop from several hours to a few days after drug discontinuation.

Apart from intensive medical and nursing care, restarting dopamine treatment is vital. However, prevention is most important and abrupt cessation of dopaminergic medication should be avoided if possible.

Serotonin Syndrome

It is essential that clinicians obtain an accurate drug history in assessing risk for Serotonin Syndrome (SS). Serotonergic drugs are frequently administered to patients with other serotonergic drugs already in their system raising the risk of toxicity [4,34]. SS generally results from drug combinations, but also occurs following overdoses and during single drug exposure [35,36]. The drugs most often associated with SS include antidepressants inhibiting serotonin reuptake [35]. Antidepressants that act as monoamine oxidase inhibitors (MAOIs) are particularly dangerous when used in drug combinations. Other drugs and herbal products are less recognized as MAOIs (methylene blue, linezolid, St. John’s wort) but are equally high risk for SS [37,38]. Opioid analgesics implicated in SS include fentanyl, tramadol, meperidine, oxycodone, dextromethorphan, and methadone [34]. While an US Food and Drug Administration advisory against co-prescribing triptan antimigraine drugs with antidepressants has been challenged, their risk of SS with MAOIs is unclear [39]. Although the incidence of SS is unknown, the risk among patients on serotonin reuptake inhibitor antidepressants has been estimated in the range of 0.09−0.23%, and up to 14−16% after overdose [40]. The onset of symptoms is usually abrupt within hours [40]. Standardized symptom criteria for serotonin toxicity are dose-related and include altered mental status (agitation, delirium), neuromuscular excitation (rigidity, tremor, hyperreflexia, clonus), and autonomic dysfunction (tachycardia, hypo/hypertension, and hyperthermia) [4,35,40-44]. Gastrointestinal symptoms may occur. Most often, patients with SS display agitation and confusion with elevated vital signs and gastrointestinal symptoms, but severe cases appear as a hyperthermic syndrome identical to NMS and MH.

Although the mechanisms are obscured by the complexity of thermoregulation, evidence implicates the serotonin 5HT-2a receptor as a primary target [4,40]. Most affected patients recover within 24 hours after drug discontinuation and initiation of supportive therapy [4,40]. Some cases benefit from cyproheptadine, a 5HT-2a blocker, while other drugs (benzodiazepines, dantrolene) may provide symptomatic relief (4,40,45). Although antipsychotics have been suggested as treatment, the risk of NMS and propensity to compromise thermoregulation and autonomic function confound any benefit.

Baclofen Withdrawal Syndrome

Baclofen is a gamma-aminobutyric acid (GABA/B) agonist used orally or intrathecally to treat severe muscle spasm in patients with spinal cord injury, cerebral palsy, traumatic brain injury, and multiple sclerosis. Chronic spinal infusion of baclofen downregulates the inhibitory effects of GABA/B receptor activity, such that abrupt withdrawal results in rebound excitation within 1−3 days and an intrathecal baclofen (ITB) withdrawal syndrome that is indistinguishable from MH and NMS [4,46]. Episodes consisting of hyperthermia, muscle rigidity, mental status and autonomic changes, respiratory distress, muscle breakdown and coagulopathies have been reported in pa-
tients withdrawn from either oral or intrathecal baclofen. ITB withdrawal may occur after mechanical malfunction of baclofen pumps or catheters, delayed refill or after removal.

Besides aggressive supportive care, definitive treatment is the restoration of baclofen administration by the same route and dosage. If enteral or intrathecal administration cannot be promptly restored, GABA- \( \alpha \)-mediated neuronal activation by parenteral benzodiazepines may be lifesaving [46].

**Adrenergic Stimulation Syndrome**

Drugs with adrenergic stimulating properties including amphetamines, cocaine (“crack”), 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”), other methamphetamine analogs (“ice”) and cathinones (“bath salts”) continue to be synthesized, sold and abused [3]. The clinical presentation of sympathomimetic intoxication consists of sweating, hypertension, tachycardia, dilated and reactive pupils, agitation, delirium, psychosis, tremors, rhabdomyolysis and hyperthermia which can progress to arrhythmias, shock, renal failure, myocardial infarction, stroke, coagulation disorders and death [47]. Hyperthermia and rhabdomyolysis result from impaired heat dissipation and ischemia due to vasoconstriction, compounded by increased heat production from agitation or seizures. While agitation and confusion are typical, some patients develop NMS or MH-like syndromes with muscle rigidity and stupor. Hyperthermia and agitation are treated with benzodiazepines, physical cooling measures, and paralysis if needed.

While MDMA has only one tenth the adrenergic stimulant effect of amphetamine, toxicity has also been attributed to serotonin toxicity leading to SS, as MDMA releases and inhibits reuptake of serotonin [47]. Hyperthermic deaths attributable to MDMA used as a “club” drug have been associated with hot settings during “rave” dance parties, implying that stimulant-driven exertional heatstroke may also play a role in its toxicity [48]. Although treatment is generally supportive, dantrolene may improve survival in some patients with extreme hyperthermia from MDMA consistent with preliminary evidence linking it to MH-susceptibility [49-52].

**Psychedelic Drug Toxicity**

Synthetic analogs of the anesthetic ketamine (“special K”), including phencyclidine (PCP, “angel dust”), continue to be abused with serious depressant, stimulant, hallucinogenic, and analgesic toxicity. Signs of intoxication are dose-related and may resemble NMS and MH. At low doses, patients may show ataxia, nystagmus, slurred speech, numbness of the extremities, hypertension, sweating, muscle rigidity, agitation or signs of catatonia or a “disassociative state”. At high doses, anesthesia, agitation, stupor, or coma may appear, accompanied by tachycardia, hypertension, sialorrhea, sweating, hyper- or hypothermia, rigidity, and convulsions 72 to 96 hours after drug ingestion [53-55]. Rhabdomyolysis progressing to renal failure is a common and serious complication of PCP intoxication [56].

Lysergic acid diethylamide (LSD) and other synthetic “designer” psychedelic drugs with serotonergic properties (phenethylamine analogs or “N-Bombs”, mescaline), may produce hyperthermia along with other effects on the autonomic nervous system [57-60]. Patients typically experience hallucinations, agitation and tachycardia, but occasionally may develop a more severe syndrome of psychosis, catatonic stupor, hyperactivity or rigidity, rhabdomyolysis, and sympathetic activation leading to hyperthermia, coagulopathies, respiratory arrest, and coma. Although hyperthermia in these cases may reflect extreme exertion, it also underscores the potential significance of serotonergic mechanisms, specifically 5HT-2a receptor activation, underlying adverse effects [61].

**Oxidative Phosphorylation Uncoupling Agents**

The process of oxidative phosphorylation in the mitochondria is essential for the production of energy-rich ATP. When this process is uncoupled from ATP production, energy is released as heat instead, causing potentially extreme increases in body temperature [3]. Salicylates, which are included in a number of marketed analgesics and anti-inflammatory products, remain a common cause of poisoning, and produce hyperthermia by uncoupling mitochondrial oxidative phosphorylation. Although patients with salicylate poisoning usually present initially with hyperventilation, tinnitus and gastrointestinal irritation, severe cases may resemble MH with hyperthermia, rhabdomyolysis, abnormal vital signs, respiratory alkalosis, metabolic acidosis, tachypnea, altered mental status, and abdominal complaints. Mild hyperthermia is common, but severe hyperthermia has been reported
Intoxication with anticholinergic drugs results in a well-described syndrome of atropinic poisoning characterized by central and peripheral signs (e.g., dry mouth, flushed dry skin, dilated and nonreactive pupils, blurred vision, tachycardia, hypertension, urinary retention, and intestinal paralysis), which may progress to ataxia, hyperactivity, agitation, increased muscle tone, hallucinations, delirium, seizures and coma [3,69,70]. Hyperthermia due to anticholinergic intoxication is usually mild and unlikely to be mistaken for NMS because of the pronounced signs of anticholinergic toxicity in the periphery and the uncommon appearance of severe temperature elevations, rhabdomyolysis, or rigidity.

Apart from supportive care and sedation, physostigmine, a reversible inhibitor of acetylcholinesterase that counteracts the effects of anticholinergics, has been studied as a specific antidote [3]. However, physostigmine should be reserved for severe agitation, tachycardia with hemodynamic instability, and extreme hyperthermia with impaired sweating because it may overcompensate for anticholinergic blockade and cause a paradoxical cholinergic crisis, including seizures and heart block, especially following tricyclic antidepressant overdose.

CONCLUSIONS

Although the differential diagnosis of hyperthermia is extensive, several drugs can induce a malignant hyperthermia-like syndrome. It is important for clinicians to recognize these syndromes and institute treatment quickly to prevent morbidity and mortality. Although these syndromes often look alike, they are triggered by quite different mechanisms, and apart from the need to withdraw or restore potential triggering drugs and provide intensive care, specific treatments may vary. It is important to know the toxicity of these drugs, especially when used in combinations, or during exertion in hot environments. Clinicians should be also be aware of dangers associated with the use of illegal and herbal substances obtained over the internet, which is unfortunately increasingly common.

Conflicts of Interest

Stanley N. Caroff served as consultant to Neurocrine Biosciences, Teva Pharmaceuticals, and received research grants from Neurocrine Biosciences, Osmotica...
Pharmaceuticals and Eagle Pharmaceuticals. Charles B. Watson and Henry Rosenberg report no conflicts or disclosures.

### Author Contributions

Conceptualization: Stanley N. Caroff, Charles B. Watson, Henry Rosenberg. Data acquisition: Stanley N. Caroff, Charles B. Watson, Henry Rosenberg. Formal analysis: Stanley N. Caroff, Charles B. Watson, Henry Rosenberg. Supervision: Stanley N. Caroff. Writing—original draft: Stanley N. Caroff. Writing—review & editing: Stanley N. Caroff, Charles B. Watson, Henry Rosenberg.

### ORCID

Stanley N. Caroff https://orcid.org/0000-0003-2840-4763
Charles B. Watson https://orcid.org/0000-0003-1445-1462
Henry Rosenberg https://orcid.org/0000-0002-3360-5378

### REFERENCES

1. Knochel JP, Reed G. Disorders of heat regulation. In: Narins RG, editor. Clinical disorders of fluid and electrolyte metabolism. 5th ed. New York:McGraw-Hill;1994.
2. Clark WG, Lipton JM. Drug-related heatstroke. Pharmacol Ther 1984;26:345-388.
3. Hayes BD, Martinez JP, Barrueto F Jr. Drug-induced hyperthermic syndromes: part I. Hyperthermia in overdose. Emerg Med Clin North Am 2013;31:1019-1033.
4. McAllen KJ, Schwartz DR. Adverse drug reactions resulting in hyperthermia in the intensive care unit. Crit Care Med 2010;38(6 Suppl):S244-S252.
5. Rusyniak DE, Sprague JE. Hyperthermia associated with other neuro-psychiatric drugs. In: Mann SC, Caroff SN, Keck PE, Lazarus A, editors. Neuroleptic malignant syndrome and related conditions. 2nd ed. Washington, D.C.:American Psychiatric Publishing, Inc.;2003. p.93-120.
6. Caroff SN. Hyperthermia associated with other neuro-psychiatric drugs. In: Mann SC, Caroff SN, Keck PE, Lazarus A, editors. Neuroleptic malignant syndrome and related conditions. 2nd ed. Washington, D.C.:American Psychiatric Publishing, Inc.;2003. p.93-120.
7. Zhao X, Song Q, Gao Y. Hypothesis: exertional heat stroke-induced myopathy and genetically inherited malignant hyperthermia represent the same disorder, the human stress syndrome. Cell Biochem Biophys 2014;70:1325-1329.
8. Meyers EF, Meyers RW. Thermic stress syndrome. JAMA 1982;247:2098-2099.
9. Breed D, Meyer LCR, Stylj ICA, Goddard A, Burroughs R, Kohn TA. Conserving wildlife in a changing world: understanding capture myopathy—a malignant outcome of stress during capture and translocation. Conserv Physiol 2019;7:coz027.
10. Riazi S, Kraeva N, Hopkins PM. Updated guide for the management of malignant hyperthermia. Can J Anaesth 2018;65:709-721.
11. Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis 2015;10:93.
12. Larach MG, Localio AR, Allen GC, Denbrough MA, Ellis FR, Gronert GA, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994;80:771-779.
13. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185-202.
14. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-876.
15. Lao KSi, Zhao J, Blais JE, Lam L, Wong ICK, Besag FMC, et al. Antipsychotics and risk of neuroleptic malignant syndrome: a population-based cohort and case-crossover study. CNS Drugs 2020;34:1165-1175.
16. Caroff SN, Rosenberg H, Mann SC, Campbell EC, Gliatto MF, Sullivan KA. Neuroleptic malignant syndrome in the perioperative setting. Am J Anaesthesiol 2001;28:387-393.
17. Caroff SN. Risk of neuroleptic malignant syndrome with vesicular monoamine transporter inhibitors. Clin Psychopharmacol Neurosci 2020;18:322-326.
18. Su YP, Chang CK, Hayes RD, Harrison S, Lee W, Broadbent M, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand 2014;130:52-60.
19. Schumacher LT, Mann AP, MacKenzie JG. Agitation management in pediatric males with anti-N-methyl-D-aspartate receptor encephalitis. J Child Adolesc Psychopharmacol 2016;26:939-943.
20. Caroff SN. Phenomenology and management of encephalitis. J Neuropsychiatry Clin Neurosci 2019;31:399.
21. Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 2011;72:1222-1228.
22. Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN. A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol 2017;37:67-71.
23. Nisijima K, Shioda K. Temporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome. Neuropsychiatr Dis Treat 2013;9:853-859.
24. Masi G, Milone A, Viglione V, Mancini A, Pisano S. Massive asymptomatic creatine kinase elevation in youth during antipsychotic drug treatment: case reports and critical review of the literature. J Child Adolesc Psychopharmacol 2014;24:536-542.
25. Mann SC: Thermoregulatory mechanisms and antipsychotic drug-related heatstroke. In Neuroleptic Malignant Syndrome and Related Conditions. Edited by Mann SC, Caroff SN, Keck PE Jr., Lazarus A. Second Edition ed. Washington, D.C., American Psychiatric Publishing, Inc.; 2003. pp. 45-74.
26. Caroff SN. Neuroleptic malignant syndrome. In: Mann SC, Caroff SN, Keck PE, Lazarus A, editors. Neuroleptic malignant syndrome and related conditions. 2nd ed. Washington, D.C.: American Psychiatric Publishing, Inc.; 2003. p.1-44.

27. Huddleston DE, Factor SA. Parkinsonism-hyperpyrexia syndrome in Parkinson’s disease. In: Frucht SJ, editor. Movement disorder emergencies: diagnosis and treatment. 2nd ed. New York: Humana Press; 2013. p.29-42.

28. Martino G, Casasso M, Nasuti M, Bonanni L, Onorfi M, Thomas A. Dopamine transporter single-photon emission computerized tomography supports diagnosis of akinetic crisis of Parkinsonism and of neuroleptic malignant syndrome. Medicine (Baltimore) 2015;94:e649.

29. Kaasinen V, Joutsu J, Neponen T, Päivärinta M. Akinetic crisis in Parkinson’s disease is associated with a severe loss of striatal dopamine transporter function: a report of two cases. Case Rep Neurol 2014;6:275-280.

30. Fujioka S, Fukae J, Mishima T, Yanamoto S, Higuchi MA, et al. Hospital-based study on emergency admission of patients with Parkinson’s disease. eNeurologicalSci 2016;4:19-21.

31. S.N. Caroff, Keck PE, Lazarus A, editors. Neuroleptic malignant syndrome. In: Mann SC, Keck PE, Lazarus A, editors. Neuroleptic malignant syndrome and related conditions. 2nd ed. Washington, D.C.: American Psychiatric Publishing, Inc.; 2003. p.1-44.

32. Alty J, Robson J, Lazarus A, Duggan-Carter P, Jamieson S. Neuroleptic malignant syndrome. In: Mann SC, Keck PE, Lazarus A, editors. Neuroleptic malignant syndrome and related conditions. 2nd ed. Washington, D.C.: American Psychiatric Publishing, Inc.; 2003. p.1-44.

33. Huddleston DE, Factor SA. Parkinsonism-hyperpyrexia syndrome in Parkinson’s disease. In: Frucht SJ, editor. Movement disorder emergencies: diagnosis and treatment. 2nd ed. New York: Humana Press; 2013. p.29-42.

34. Baldo BA, Rose MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. Br J Anaesth 2016;116:122-128.

35. Artusi CA, Beranzoli A, Alongi A, Lanotte M, et al. Parkinsonism-hyperpyrexia syndrome and deep brain stimulation. J Neurol 2015;262:2780-2782.

36. Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database. J Clin Psychopharmacol 2015;35:382-388.

37. Direk MC, Yildirim V, Güneş S, Bozlu G, Okuyaz Ç. Serotonin syndrome after clomipramine overdose in a child. Clin Psychopharmacol Neurosci 2016;14:388-390.

38. Basta MN. Postoperative serotonin syndrome following methylene blue administration for vasoplegia after cardiac surgery: a case report and review of the literature. Semin Cardiothorac Vasc Anesth 2020. doi: 10.1177/1089253220960255. [Epub ahead of print]

39. Gatti M, Raschi E, De Ponti F. Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol 2020. doi: 10.1007/s00228-020-02990-1. [Epub ahead of print]

40. Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol 2018;75:566-572.

41. Francescangeli J, Karamchandani K, Powell M, Bonavita A. The serotonin syndrome: from molecular mechanisms to clinical practice. Int J Mol Sci 2019;20:2288.

42. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-1120.

43. Nguyen H, Pan A, Smollin C, Cantrell LF, Kearney T. An 11-year retrospective review of cyproheptadine use in serotonin syndrome cases reported to the California Poison Control System. J Clin Pharm Ther 2019;44:327-334.

44. Coffey RJ, Edgar TS, Francisco GE, Graziani V, Meythaler JM, Ridgely PM, et al. Abrupt withdrawal from intrathalcal baclofen: recognition and management of a potentially life-threatening event. J Med Toxicol 2006;2:252-258.

45. Coffey RJ, Edgar TS, Francisco GE, Graziani V, Meythaler JM, Ridgely PM, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening event. J Med Toxicol 2006;2:252-258.

46. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-1120.

47. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-1120.

48. Turkington methods and serotonin syndrome. JAMA Neurol 2018;75:1060-1061.

49. Turkington methods and serotonin syndrome. JAMA Neurol 2018;75:1060-1061.

50. Turkington methods and serotonin syndrome. JAMA Neurol 2018;75:1060-1061.

51. Turkington methods and serotonin syndrome. JAMA Neurol 2018;75:1060-1061.

52. Turkington methods and serotonin syndrome. JAMA Neurol 2018;75:1060-1061.

53. Turkington methods and serotonin syndrome. JAMA Neurol 2018;75:1060-1061.

54. Turkington methods and serotonin syndrome. JAMA Neurol 2018;75:1060-1061.

55. Turkington methods and serotonin syndrome. JAMA Neurol 2018;75:1060-1061.
enedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm 2002;59:1067-1076.

56. Akmal M, Valdin JR, McCarron MM, Massry SG. Rhabdomyolysis with and without acute renal failure in patients with phencyclidine intoxication. Am J Nephrol 1981;1:91-96.

57. Leonard JB, Anderson B, Klein-Schwartz W. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. J Psychopharmacol 2018;32:1286-1294.

58. Rosenberg J, Pentel P, Pond S, Benowitz N, Olson K. Hyperthermia associated with drug intoxication. Crit Care Med 1986;14:964-969.

59. Zawilska JB, Kacela M, Adamowicz P. NBOMes-highly potent and toxic alternatives of LSD. Front Neurosci 2020;14:78.

60. Katarzyna K, Paweł S, Kamilla M. 25I-NBOME (2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxyphenyl)methylethanamine)-a harmful hallucinogen review. J Anal Toxicol 2020. doi: 10.1093/jat/bkaa022. [Epub ahead of print]

61. López-Giménez JF, González-Maeso J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci 2018;36:45-73.

62. Candy JM, Morrison C, Paton RD, Logan RW, Lawson R. Salicylate toxicity masquerading as malignant hyperthermia. Paediatr Anaesth 1998;8:421-423.

63. Kamour A, George N, Gwynnette D, Cooper G, Lupton D, Eddleston M, et al. Increasing frequency of severe clinical toxicity after use of 2,4-dinitrophenol in the UK: a report from the National Poisons Information Service. Emerg Med J 2015;32:383-386.

64. Sousa D, Carmo H, Roque Bravo R, Carvalho F, Bastos ML, Guedes de Pinho P, et al. Diet aid or aid to die: an update on 2,4-dinitrophenol (2,4-DNP) use as a weight-loss product. Arch Toxicol 2020;94:1071-1083.

65. Kopec KT, Kim T, Mowry J, Aks S, Kao L. Role of dantrolene in dinitrophenol (DNP) overdose: a continuing question? Am J Emerg Med 2019;37:1216.e1-1216.e2.

66. Van Schoor J, Khanderia E, Thorniley A. Dantrolene is not the answer to 2,4-dinitrophenol poisoning: more heated debate. BMJ Case Rep 2018;11:e225323.

67. Torline RL. Extreme hyperpyrexia associated with central anticholinergic syndrome. Anesthesiology 1992;76:470-471.

68. Mann SC, Boger WP. Psychotropic drugs, summer heat and humidity, and hyperpyrexia: a danger restated. Am J Psychiatry 1978;135:1097-1100.

69. Shader RI, Greenblatt DJ. Uses and toxicity of belladonna alkaloids and synthetic anticholinergics. Semin Psychiatry 1971;3:449-476.

70. Greenblatt DJ, Shader RI. Drug therapy. Anticholinergics. N Engl J Med 1973;288:1215-1219.